Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis-Reference-Cited by-同舟云学术

Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis

Published:2021-09-09 Issue:2 Volume:51 Page:189-192
ISSN:0253-5068
Container-title:Blood Purification
language:en
Short-container-title:Blood Purif

Author:

Li Sijia,Chen Xueqin,Hu Penghua,Wu Suijing,Ma Jianchao,Li Zhuo,Wu Xiuchuan,Wen Feng,Fu Xia,Feng Zhonglin,Tao Yiming,Li Bohou,Fu Lei,Huang Renwei,He Chaosheng,Shi Wei,Liang Xinling^ORCID,Liu Shuangxin^ORCID

Abstract

Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.

Publisher

S. Karger AG

Subject

Nephrology,Hematology,General Medicine

Reference9 articles.

1. Peces R, de la Torre M, Alcázar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med. 1996 Aug;335(7):523–4.

2. Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004 May;363(9423):1768–71.

3. Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015 Oct;30(10):1665–73.

4. Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019 Sept;381(11):1011–22.

5. Casadevall N, Cournoyer D, Marsh J, Messner H, Pallister C, Parker-Williams J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004 Dec;73(6):389–96.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meticulous catheter care and aseptic approach reduce catheter-related bloodstream infections significantly in hemodialysis patients: A 5-year single center study;The Journal of Vascular Access;2024-05-27

2. Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration;Annals of Hematology;2023-07-03

3. Roxadustat: do we know all the answers?;Biomolecules and Biomedicine;2023-01-03

4. Epoetin-α;Reactions Weekly;2022-10-29

5. Case Report: Roxadustat in Combination With Rituximab Was Used to Treat EPO-Induced Pure Red Cell Aplasia;Frontiers in Nephrology;2022-03-24